为解决平衡感分子机制未完全明晰的问题，山东大学研究人员开展关于平衡感相关受体的研究。发现力敏感 GPCR——LPHN2 对维持正常平衡至关重要。该研究为理解平衡感及治疗眩晕等疾病提供新思路，值得科研读者一读。

在动荡的市场环境下，Structure Therapeutics ADR（股票代码：GPCR）股价跌至52周新低，触及23.48美元。根据 InvestingPro 数据显示，该股从52周高点62.74美元大幅下跌，分析师给出的目标价区间为50美元至118美元。这一显著跌势反映了投资者普遍谨慎的态度，因为该公司正在应对制药板块面临的诸多挑战。过去一年，GPCR的市值大幅缩水，一年跌幅达48.58% ...

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. A mere six months ago Verily ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

After hours: 7:56:44 p.m. EST ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...

Spire Wealth Management bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,949 shares of the company’s ...

EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC. Exicure, Inc. (Nasdaq: XCUR, "the Company", "Exicure"), today announced that on January 19 ...